Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 36.43B +61.4% |
| Revenue (ttm) | 45.58B -2.2% |
| Net Income | -3.62B |
| EPS | -3.68 |
| Shares Out | 982.42M |
| PE Ratio | n/a |
| Forward PE | 8.47 |
| Dividend | 0.11 (0.30%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 4,605,749 |
| Average Volume | 2,607,617 |
| Open | 36.90 |
| Previous Close | 37.08 |
| Day's Range | 36.90 - 39.65 |
| 52-Week Range | 22.02 - 49.78 |
| Beta | 0.84 |
| RSI | 49.46 |
| Earnings Date | May 12, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial StatementsNews
Q1 2026 Bayer AG Earnings Call Transcript
Q1 2026 Bayer AG Earnings Call Transcript
European Markets Decline Amid Iran Tensions; Bayer (BAYRY) Surges on Strong Earnings
European Markets Decline Amid Iran Tensions; Bayer (BAYRY) Surges on Strong Earnings
Bayer Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% sales growth and higher EPS, driven by Crop Science and Consumer Health, while Pharma remained flat. Litigation settlements and FX headwinds weighed on cash flow, but full-year guidance is confirmed as the company navigates geopolitical and market uncertainties.
Bayer Shares Jump 5% After â¬4.45 Billion Profit Beat
Bayer Shares Jump 5% After â¬4.45 Billion Profit Beat
Bayer AG (BAYZF) Reports Q1 Earnings with Positive EBITDA Growth
Bayer AG (BAYZF) Reports Q1 Earnings with Positive EBITDA Growth
Bayer Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% sales growth and a 13% rise in core EPS, driven by Crop Science and licensing income. Litigation settlements weighed on cash flow, but guidance for 2026 is reaffirmed despite FX and geopolitical risks. Crop Science, Pharma, and Consumer Health all contributed to performance.
Bayer Reports Strong Q1 Profit Boosted by Antibiotics Sale
Bayer Reports Strong Q1 Profit Boosted by Antibiotics Sale
Bayer (BAYRY) Reports Strong Q1 Earnings Driven by Agricultural Growth
Bayer (BAYRY) Reports Strong Q1 Earnings Driven by Agricultural Growth
Bayer Earnings Top Estimates on Crop Science, Soybean Gains
Bayer AG posted better-than-expected profit in the first quarter, underpinned by a robust performance in its crop science unit, including a boost from soybean seeds and traits.
Bayer Q1 Profit Jumps; Confirms Full-Year Outlook At Constant Currencies
LEVERKUSEN (dpa-AFX) - Bayer AG (BYR.L) on Tuesday reported significantly-higher first-quarter profit, primarily helped by special gains.Net income attributable to shareholders rose to €2.763 bill...
Bayer Net Profit Surges Driven by Growth in Agricultural Division
The group's net profit was aided by a gain from the sale of an antibiotics business and stronger underlying earnings at its agricultural division.
Bayer Q1 operating profit up 9% as crop protection unit gains
Bayer on Tuesday said first-quarter operating profit gained 9%, driven mainly by its agricultural business.
Can India’s rice farmers reap from US$30 million Amazon carbon credit deal?
A US$30 million carbon credit deal by tech giant Amazon with India’s Good Rice Alliance will boost carbon markets globally, according to experts, potentially showing agriculture – as well as industry ...
Bayer reports REVEAL study met primary endpoints
Bayer (BAYRY) announced topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evu...
Bayer to acquire Perfuse Therapeutics for $300M upfront
Bayer (BAYRY) and Perfuse Therapeutics announced an agreement under which Bayer will fully acquire Perfuse Therapeutics. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a...
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women's Hospital that evaluated...
Bayer and bp Form Strategic Alliance to Jointly Scale Camelina as Intermediate Crop for Biofuels
ST. LOUIS--(BUSINESS WIRE)--Bayer, a life science company, and bp, a global integrated energy company, today announced that they have entered into a long-term strategic alliance to jointly scale the c...
Bayer says its experimental blood thinner cuts risk and severity of repeat strokes
Bayer said on Wednesday new analyses showed its experimental blood thinner asundexian reduced the incidence and severity of ischaemic strokes.
Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Bayer said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology pipeline.
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneer...
House strips MAHA-hated pesticide provisions from farm bill
MAHA advocates said the language that was stripped could have provided liability protection for Bayer in lawsuits involving its Roundup weedkiller.
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new la...
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
BERLIN--(BUSINESS WIRE)--A new study from Leaps by Bayer and BCG reveals varying trends in how the public views breakthrough science in China, Germany, and the United States.
Bayer upgraded to Buy from Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded Bayer (BAYRY) to Buy from Neutral with a EUR 56 price target